Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent or Refractory B-cell Non Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00036946
What this trial is testing

VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
Regeneron Pharmaceuticals
Early research (Phase 1)Study completedNCT00390117
What this trial is testing

AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
NCIC Clinical Trials Group 34
Testing effectiveness (Phase 2)Ended earlyNCT00265928
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
University of Virginia 46
Early research (Phase 1)Study completedNCT01231919
What this trial is testing

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative Disorder+48 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)UnknownNCT00002481
What this trial is testing

Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
St. Luke's Medical Center
Early research (Phase 1)Temporarily pausedNCT00077493
What this trial is testing

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
MedImmune LLC 95
Testing effectiveness (Phase 2)Study completedNCT02445248
What this trial is testing

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Who this might be right for
Diffuse Large B-cell Lymphoma (DLBCL)
Novartis Pharmaceuticals 115
Testing effectiveness (Phase 2)UnknownNCT01678404
What this trial is testing

131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Who this might be right for
Relapsed or Refractory Marginal Zone B-cell Lymphoma
Korea Cancer Center Hospital 28
Early research (Phase 1)Study completedNCT00054236
What this trial is testing

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+3 more
Case Comprehensive Cancer Center 55
Early research (Phase 1)Looking for participantsNCT06980116
What this trial is testing

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed or Refractory B-cell MalignanciesChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Follicular Lymphoma (FL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 85
Early research (Phase 1)Study completedNCT00020111
What this trial is testing

Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma

Who this might be right for
LeukemiaLymphoma
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT04205838
What this trial is testing

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaProgressive Disease+8 more
Jonsson Comprehensive Cancer Center 23
Testing effectiveness (Phase 2)Study completedNCT00867529
What this trial is testing

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic Leukemia+35 more
Fred Hutchinson Cancer Center 63
Large-scale testing (Phase 3)Study completedNCT03575351
What this trial is testing

Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 184
Early research (Phase 1)Study completedNCT00003294
What this trial is testing

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer

Who this might be right for
LeukemiaLymphomaUnspecified Adult Solid Tumor, Protocol Specific
Roswell Park Cancer Institute 24
Early research (Phase 1)Study completedNCT02219737
What this trial is testing

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
CD20 PositiveRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 26
Early research (Phase 1)Study completedNCT00058227
What this trial is testing

Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaContiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular Lymphoma+40 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT05192486
What this trial is testing

GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd. 12
Not applicableStudy completedNCT07103486
What this trial is testing

Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Novartis Pharmaceuticals 264
Testing effectiveness (Phase 2)Study completedNCT02207062
What this trial is testing

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
University of Washington 20
Next Page